The current landscape of nucleic acid therapeutics
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Machine scores (provisional)
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
- Teacher spread
- 0.305 · how far apart the two teachers sit on this one work
- Validation status
score_only:v0-immature-baseline· verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it
Abstract
The increasing number of approved nucleic acid therapeutics demonstrates the potential to treat diseases by targeting their genetic blueprints in vivo. Conventional treatments generally induce therapeutic effects that are transient because they target proteins rather than underlying causes. In contrast, nucleic acid therapeutics can achieve long-lasting or even curative effects via gene inhibition, addition, replacement or editing. Their clinical translation, however, depends on delivery technologies that improve stability, facilitate internalization and increase target affinity. Here, we review four platform technologies that have enabled the clinical translation of nucleic acid therapeutics: antisense oligonucleotides, ligand-modified small interfering RNA conjugates, lipid nanoparticles and adeno-associated virus vectors. For each platform, we discuss the current state-of-the-art clinical approaches, explain the rationale behind its development, highlight technological aspects that facilitated clinical translation and provide an example of a clinically relevant genetic drug. In addition, we discuss how these technologies enable the development of cutting-edge genetic drugs, such as tissue-specific nucleic acid bioconjugates, messenger RNA and gene-editing therapeutics. This Review provides an overview of four platform technologies that are currently used in the clinic for delivery of nucleic acid therapeutics, describing their properties, discussing technical advancements that led to clinical approval, and highlighting examples of approved genetic drugs that make use of these technologies.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
The record
- Venue
- Nature Nanotechnology
- Topic
- RNA Interference and Gene Delivery
- Field
- Biochemistry, Genetics and Molecular Biology
- Canadian institutions
- BC Children's HospitaliCo Therapeutics (Canada)University of British Columbia
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen ForschungHuntington Society of CanadaGovernment of CanadaFondation Brain CanadaNederlandse Organisatie voor Wetenschappelijk OnderzoekWeston Brain InstituteCanadian Institutes of Health ResearchNanoMedicines Innovation Network
- Keywords
- Nucleic acidComputational biologyOligonucleotideTranslation (biology)RNA interferenceSmall interfering RNANanotechnologyBiologyRNAComputer scienceBioinformaticsDNAGeneGeneticsMessenger RNAMaterials science
- Has abstract in OpenAlex
- yes